| SMAD2 and NOTCH4 |
SMAD family member 2 |
notch 4 |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Notch-HLH transcription pathway
- Signaling by NOTCH4
- Generic Transcription Pathway
- Pre-NOTCH Processing in Golgi
- Pre-NOTCH Transcription and Translation
- Signaling by NOTCH
- Pre-NOTCH Processing in the Endoplasmic Reticulum
- Pre-NOTCH Expression and Processing
|
|
|
|
|
| SMAD2 and RBL1 |
SMAD family member 2 |
retinoblastoma-like 1 |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Mitotic G1-G1/S phases
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- G1 Phase
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- G0 and Early G1
- Loss of Function of TGFBR1 in Cancer
- Cell Cycle, Mitotic
- Cyclin D associated events in G1
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
| SMAD2 and ITCH |
SMAD family member 2 |
itchy E3 ubiquitin protein ligase |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Hedgehog 'off' state
- Antigen processing: Ubiquitination & Proteasome degradation
- Negative regulators of RIG-I/MDA5 signaling
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- NOD1/2 Signaling Pathway
- Signaling by NOTCH1
- Hedgehog 'on' state
- Signaling by NOTCH1 in Cancer
- Class I MHC mediated antigen processing & presentation
- FBXW7 Mutants and NOTCH1 in Cancer
- Innate Immune System
- Downregulation of ERBB4 signaling
- Signaling by NOTCH
- Signaling by ERBB4
- Activated NOTCH1 Transmits Signal to the Nucleus
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by Hedgehog
- Degradation of GLI1 by the proteasome
- Adaptive Immune System
|
|
|
|
|
| SMAD2 and RARB |
SMAD family member 2 |
retinoic acid receptor, beta |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Generic Transcription Pathway
- Signaling by Retinoic Acid
- Nuclear Receptor transcription pathway
- Orphan transporters
|
|
- Adapalene
- Acitretin
- Alitretinoin
- Tazarotene
- Etretinate
- TTNPB
- Tamibarotene
|
|
|
| SMAD2 and NEDD4L |
SMAD family member 2 |
neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Loss of Function of TGFBR2 in Cancer
- Antigen processing: Ubiquitination & Proteasome degradation
- HIV Infection
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- HIV Life Cycle
- Budding and maturation of HIV virion
- Ion channel transport
- Generic Transcription Pathway
- Stimuli-sensing channels
- Class I MHC mediated antigen processing & presentation
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Late Phase of HIV Life Cycle
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
- Adaptive Immune System
|
|
|
|
|
| SMAD2 and MAPK3 |
SMAD family member 2 |
mitogen-activated protein kinase 3 |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Signaling by FGFR in disease
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- Cellular Senescence
- ERKs are inactivated
- Signaling by EGFRvIII in Cancer
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Fcgamma receptor (FCGR) dependent phagocytosis
- SHC-mediated signalling
- Regulation of actin dynamics for phagocytic cup formation
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- Senescence-Associated Secretory Phenotype (SASP)
- ERK1 activation
- Signaling by VEGF
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- L1CAM interactions
- Oncogene Induced Senescence
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- ERKs are inactivated
- Signal transduction by L1
- Insulin receptor signalling cascade
- ISG15 antiviral mechanism
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- Signaling by FGFR
- Thrombin signalling through proteinase activated receptors (PARs)
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Antiviral mechanism by IFN-stimulated genes
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Growth hormone receptor signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- RNA Polymerase I Promoter Clearance
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Advanced glycosylation endproduct receptor signaling
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- RNA Polymerase I Transcription
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- Cellular response to heat stress
- Regulation of HSF1-mediated heat shock response
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- Oxidative Stress Induced Senescence
- RNA Polymerase I Promoter Opening
- Nuclear Events (kinase and transcription factor activation)
|
|
- Sulindac
- Arsenic trioxide
- Purvalanol
- 5-iodotubercidin
|
|
|
| SMAD2 and RANBP9 |
SMAD family member 2 |
RAN binding protein 9 |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Axon guidance
- L1CAM interactions
|
|
|
|
|
| SMAD2 and PARD3 |
SMAD family member 2 |
par-3 family cell polarity regulator |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Loss of Function of TGFBR2 in Cancer
- Cell junction organization
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Tight junction interactions
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Cell-cell junction organization
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
| SMAD2 and SMURF1 |
SMAD family member 2 |
SMAD specific E3 ubiquitin protein ligase 1 |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Loss of Function of TGFBR2 in Cancer
- Antigen processing: Ubiquitination & Proteasome degradation
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- Signaling by Wnt
- TGFBR1 LBD Mutants in Cancer
- Signaling by BMP
- Hedgehog 'on' state
- Class I MHC mediated antigen processing & presentation
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- beta-catenin independent WNT signaling
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Asymmetric localization of PCP proteins
- Signaling by Hedgehog
- PCP/CE pathway
- SMAD4 MH2 Domain Mutants in Cancer
- Adaptive Immune System
|
|
|
|
|
| SMAD2 and PPM1A |
SMAD family member 2 |
protein phosphatase, Mg2+/Mn2+ dependent, 1A |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Loss of Function of TGFBR2 in Cancer
- IRS-mediated signalling
- mTOR signalling
- SMAD2/3 MH2 Domain Mutants in Cancer
- mTOR signalling
- TGFBR1 LBD Mutants in Cancer
- IGF1R signaling cascade
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- IRS-related events triggered by IGF1R
- Generic Transcription Pathway
- Energy dependent regulation of mTOR by LKB1-AMPK
- PKB-mediated events
- PI3K Cascade
- Signaling by Insulin receptor
- TGFBR2 MSI Frameshift Mutants in Cancer
- Insulin receptor signalling cascade
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Regulation of AMPK activity via LKB1
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- IRS-related events
- Loss of Function of TGFBR1 in Cancer
- IRS-mediated signalling
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PKB-mediated events
- PI3K Cascade
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
| SMAD2 and TGFBR1 |
SMAD family member 2 |
transforming growth factor, beta receptor 1 |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Loss of Function of TGFBR2 in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
| SMAD2 and TGIF1 |
SMAD family member 2 |
TGFB-induced factor homeobox 1 |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Loss of Function of TGFBR1 in Cancer
- Generic Transcription Pathway
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
| SMAD2 and PPP2R1A |
SMAD family member 2 |
protein phosphatase 2, regulatory subunit A, alpha |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Signaling by FGFR in disease
- Integration of energy metabolism
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- ERKs are inactivated
- Toll Like Receptor TLR1:TLR2 Cascade
- Glucose metabolism
- Degradation of beta-catenin by the destruction complex
- Toll Like Receptor 5 (TLR5) Cascade
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- MyD88 dependent cascade initiated on endosome
- Glycogen storage diseases
- Beta-catenin phosphorylation cascade
- Mitotic G1-G1/S phases
- Recruitment of mitotic centrosome proteins and complexes
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TRIF-mediated TLR3/TLR4 signaling
- S45 mutants of beta-catenin aren't phosphorylated
- Spry regulation of FGF signaling
- Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- Platelet sensitization by LDL
- Resolution of Sister Chromatid Cohesion
- Toll Like Receptor 3 (TLR3) Cascade
- Metabolism of carbohydrates
- Mitotic G2-G2/M phases
- Adaptive Immune System
- MASTL Facilitates Mitotic Progression
- Separation of Sister Chromatids
- APC truncation mutants have impaired AXIN binding
- G2/M Transition
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- Activated TLR4 signalling
- S37 mutants of beta-catenin aren't phosphorylated
- Cyclin A/B1 associated events during G2/M transition
- Loss of Nlp from mitotic centrosomes
- XAV939 inhibits tankyrase, stabilizing AXIN
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Innate Immune System
- Nonsense-Mediated Decay (NMD)
- E2F mediated regulation of DNA replication
- ERKs are inactivated
- G1 Phase
- CTLA4 inhibitory signaling
- Signaling by FGFR
- Cyclin D associated events in G1
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- TCF dependent signaling in response to WNT
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by WNT in cancer
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
- Signaling by GPCR
- Mitotic Prophase
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- Glycolysis
- Regulation of PLK1 Activity at G2/M Transition
- RNF mutants show enhanced WNT signaling and proliferation
- G1/S Transition
- Myoclonic epilepsy of Lafora
- Toll Like Receptor 9 (TLR9) Cascade
- Initiation of Nuclear Envelope Reformation
- ERK/MAPK targets
- truncations of AMER1 destabilize the destruction complex
- Negative regulation of FGFR signaling
- Opioid Signalling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- Toll Like Receptor 2 (TLR2) Cascade
- Platelet homeostasis
- Toll Like Receptor 4 (TLR4) Cascade
- Mitotic Metaphase and Anaphase
- PP2A-mediated dephosphorylation of key metabolic factors
- Mitotic Prometaphase
- Organelle biogenesis and maintenance
- Costimulation by the CD28 family
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Mitotic Anaphase
- APC truncation mutants are not K63 polyubiquitinated
- M Phase
- Toll Like Receptor TLR6:TLR2 Cascade
- MyD88 cascade initiated on plasma membrane
- DARPP-32 events
- Nuclear Envelope Reassembly
- Signalling by NGF
- MAP kinase activation in TLR cascade
- Assembly of the primary cilium
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Anchoring of the basal body to the plasma membrane
- Cell Cycle, Mitotic
- Loss of proteins required for interphase microtubule organization from the centrosome
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Centrosome maturation
- Nuclear Events (kinase and transcription factor activation)
|
|
|
|
|
| SMAD2 and STRAP |
SMAD family member 2 |
serine/threonine kinase receptor associated protein |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
| SMAD2 and HGS |
SMAD family member 2 |
hepatocyte growth factor-regulated tyrosine kinase substrate |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Signaling by EGFR
- EGFR downregulation
- Endosomal Sorting Complex Required For Transport (ESCRT)
- Signaling by EGFR in Cancer
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by EGFRvIII in Cancer
|
|
|
|
|
| SMAD2 and MAPK1 |
SMAD family member 2 |
mitogen-activated protein kinase 1 |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- phospho-PLA2 pathway
- Ca-dependent events
- Signaling by FGFR in disease
- Cellular Senescence
- ERKs are inactivated
- CREB phosphorylation through the activation of Ras
- Signaling by EGFRvIII in Cancer
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Fcgamma receptor (FCGR) dependent phagocytosis
- SHC-mediated signalling
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Regulation of actin dynamics for phagocytic cup formation
- TRIF-mediated TLR3/TLR4 signaling
- Senescence-Associated Secretory Phenotype (SASP)
- Signaling by VEGF
- Signalling to RAS
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Transmission across Chemical Synapses
- Axon guidance
- IRS-mediated signalling
- L1CAM interactions
- Oncogene Induced Senescence
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- RSK activation
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- NCAM signaling for neurite out-growth
- Signalling to p38 via RIT and RIN
- RAF/MAP kinase cascade
- Innate Immune System
- Signaling by Insulin receptor
- ERKs are inactivated
- Signal transduction by L1
- Insulin receptor signalling cascade
- PLC beta mediated events
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- G-protein mediated events
- Signaling by FGFR
- Thrombin signalling through proteinase activated receptors (PARs)
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by GPCR
- Mitotic Prophase
- Golgi Cisternae Pericentriolar Stack Reorganization
- FCERI mediated MAPK activation
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- Opioid Signalling
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Signaling by Leptin
- Growth hormone receptor signaling
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Recycling pathway of L1
- M Phase
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Advanced glycosylation endproduct receptor signaling
- Post NMDA receptor activation events
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- Cellular response to heat stress
- Regulation of HSF1-mediated heat shock response
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- Oxidative Stress Induced Senescence
- ERK2 activation
- Nuclear Events (kinase and transcription factor activation)
|
|
- Isoproterenol
- Arsenic trioxide
- Olomoucine
- Phosphonothreonine
- Purvalanol
- SB220025
- N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
- (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
- 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
- (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
|
|
|
| SMAD2 and LEF1 |
SMAD family member 2 |
lymphoid enhancer-binding factor 1 |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- Degradation of beta-catenin by the destruction complex
- S37 mutants of beta-catenin aren't phosphorylated
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- TCF dependent signaling in response to WNT
- AMER1 mutants destabilize the destruction complex
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
|
|
|
|
| SMAD2 and TP53 |
SMAD family member 2 |
tumor protein p53 |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Cellular Senescence
- Activation of BH3-only proteins
- p53-Dependent G1/S DNA damage checkpoint
- Oncogene Induced Senescence
- p53-Dependent G1 DNA Damage Response
- Formation of Senescence-Associated Heterochromatin Foci (SAHF)
- Pre-NOTCH Transcription and Translation
- Stabilization of p53
- Transcriptional activation of p53 responsive genes
- Programmed Cell Death
- Pre-NOTCH Expression and Processing
- G1/S DNA Damage Checkpoints
- Intrinsic Pathway for Apoptosis
- Transcriptional activation of cell cycle inhibitor p21
- DNA Damage/Telomere Stress Induced Senescence
- Signaling by NOTCH
- Factors involved in megakaryocyte development and platelet production
- Activation of NOXA and translocation to mitochondria
- Oxidative Stress Induced Senescence
- Autodegradation of the E3 ubiquitin ligase COP1
- Activation of PUMA and translocation to mitochondria
- Cell Cycle Checkpoints
|
|
|
|
|
| SMAD2 and SMAD3 |
SMAD family member 2 |
SMAD family member 3 |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
| SMAD3 and AXIN2 |
SMAD family member 3 |
axin 2 |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- formation of the beta-catenin:TCF transactivating complex
- XAV939 inhibits tankyrase, stabilizing AXIN
- degradation of AXIN
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- Signaling by WNT in cancer
|
|
|
|
|